Skip to main content
Top
Published in: Reviews in Endocrine and Metabolic Disorders 2/2019

Open Access 01-06-2019 | Insulins

Can blood glucose value really be referred to as a metabolic parameter?

Authors: Kornél Simon, István Wittmann

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 2/2019

Login to get access

Abstract

In clinical guidelines, near-normoglycaemia is recommended as the basic therapeutic target in diabetes mellitus. This proposal suggests that euglycaemia is associated with eumetabolism and that hyperglycaemia is an indicator of dysmetabolism. The authors analysed the relationship between short/long-term blood glucose values and cellular metabolism in various pathophysiological settings. The following types of dysmetabolism are suggested: “hyperglycaemic dysmetabolism based on insulin deficiency”, “hyperglycaemic dysmetabolism based on glucose toxicity”, “euglycaemic dysmetabolism”, “dysmetabolism of ischaemic/reperfusional origin”, and “chronic stress-mediated dysmetabolism”. The relationship between dysmetabolic states of various origin was also analysed. The authors conclude that the blood glucose value can only be accepted as a general metabolic parameter with marked limitations. The main arguments of this statement are that euglycaemia is not necessarily associated with eumetabolism and that acute hyperglycaemia does not necessarily indicate dysmetabolism. Identical cell metabolic performance can be supported by different biochemical energy-producing mechanisms associated with identical blood glucose values. Both positive and negative metabolic balance of cell metabolism can occur at identical blood glucose values. A further finding is that chronic hyperglycaemia acts simultaneously as a marker and as a maker of dysmetabolism; therefore, the achievement of near normoglycaemia remains the basic therapeutic goal in diabetes treatment. Insulin administration can beneficially influence dysmetabolic states of various origins. In the evolution of and interrelationships among various dysmetabolic states, the central role of chronic stress is emphasized. Discrepancies between blood glucose values and cellular metabolism are substantiated by the transporter nature of the blood glucose value; this value reflects the result of bidirectional glucose movement into and out of the tissues.
Literature
1.
go back to reference Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. Eur Heart J. 2013;34:3035–87.CrossRefPubMed Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. Eur Heart J. 2013;34:3035–87.CrossRefPubMed
2.
go back to reference Wittmann I. The potential common mechanism of hormonal resistance, and it’s suggested role in pathogenesis of metabolic syndrome and cardiovasular diseases. Diabet Hung. 2014;22:173–79. Wittmann I. The potential common mechanism of hormonal resistance, and it’s suggested role in pathogenesis of metabolic syndrome and cardiovasular diseases. Diabet Hung. 2014;22:173–79.
3.
go back to reference Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation. 2004;110:894–6.CrossRefPubMed Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation. 2004;110:894–6.CrossRefPubMed
4.
go back to reference von Bibra H, Sutton MSJ. Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia. 2010;53:1033–45.CrossRef von Bibra H, Sutton MSJ. Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia. 2010;53:1033–45.CrossRef
5.
go back to reference Horowitz JD, Chirkov YY, Kennedy JA, Sverdlov AL. Modulation of myocardial metabolism: an emerging therapeutic principle. Curr Opin Cardiol. 2010;25:329–34.CrossRefPubMed Horowitz JD, Chirkov YY, Kennedy JA, Sverdlov AL. Modulation of myocardial metabolism: an emerging therapeutic principle. Curr Opin Cardiol. 2010;25:329–34.CrossRefPubMed
7.
go back to reference Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol. 1996;28:1661–9.CrossRefPubMed Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol. 1996;28:1661–9.CrossRefPubMed
8.
go back to reference Haffner SM. Abdominal obesity, insulin resistance, and cardiovascular risk in pre-diabetes and type 2 diabetes. Eur Heart J Suppl. 2006;8:B20–5.CrossRef Haffner SM. Abdominal obesity, insulin resistance, and cardiovascular risk in pre-diabetes and type 2 diabetes. Eur Heart J Suppl. 2006;8:B20–5.CrossRef
9.
go back to reference van den Berghe G. Insulin vs. strict blood glucose control to achieve a survival benefit after AMI? Eur Heart J. 2005;26:639–41.CrossRefPubMed van den Berghe G. Insulin vs. strict blood glucose control to achieve a survival benefit after AMI? Eur Heart J. 2005;26:639–41.CrossRefPubMed
10.
go back to reference Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP, Heart SA. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart study. Circulation. 2004;110:1251–7.CrossRefPubMed Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP, Heart SA. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart study. Circulation. 2004;110:1251–7.CrossRefPubMed
11.
go back to reference Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, et al. The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3′-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. J Pharmacol Exp Ther. 2008;324:234–43.CrossRefPubMed Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, et al. The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3′-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. J Pharmacol Exp Ther. 2008;324:234–43.CrossRefPubMed
13.
go back to reference Graymore CN. In: Graymore CN, editor. Biochemistry of the eye Biochemistry of the retina. New York, NY: Academic Press; 1970. p. 645–735. Graymore CN. In: Graymore CN, editor. Biochemistry of the eye Biochemistry of the retina. New York, NY: Academic Press; 1970. p. 645–735.
14.
go back to reference Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med. 1998;15:188–93.CrossRefPubMed Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med. 1998;15:188–93.CrossRefPubMed
15.
go back to reference Ihnat MA, Thorpe JE, Ceriello A. Hypothesis: the 'metabolic memory', the new challenge of diabetes. Diabet Med. 2007;24:582–6.CrossRefPubMed Ihnat MA, Thorpe JE, Ceriello A. Hypothesis: the 'metabolic memory', the new challenge of diabetes. Diabet Med. 2007;24:582–6.CrossRefPubMed
16.
go back to reference Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRefPubMed Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRefPubMed
17.
go back to reference Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355:773–8.CrossRefPubMed Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355:773–8.CrossRefPubMed
18.
19.
go back to reference Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–46.CrossRefPubMed Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–46.CrossRefPubMed
20.
go back to reference Tattersall RB. Type 2 diabetes or NIDDM: looking for a better name. Lancet. 1989;1:589–91. Tattersall RB. Type 2 diabetes or NIDDM: looking for a better name. Lancet. 1989;1:589–91.
21.
go back to reference Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: the "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94:410–5.CrossRefPubMed Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: the "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94:410–5.CrossRefPubMed
22.
go back to reference Mazzone T. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance. Am J Cardiol 2004;93:27C–31C. Mazzone T. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance. Am J Cardiol 2004;93:27C–31C.
23.
go back to reference Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation. 2003;107:1100–2.CrossRefPubMed Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation. 2003;107:1100–2.CrossRefPubMed
24.
go back to reference Lager I. The insulin-antagonistic effect of the counterregulatory hormones. J Intern Med Suppl. 1991;735:41–7.PubMed Lager I. The insulin-antagonistic effect of the counterregulatory hormones. J Intern Med Suppl. 1991;735:41–7.PubMed
25.
go back to reference DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Phys. 1979;237:E214–23. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Phys. 1979;237:E214–23.
26.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet. 1998;352:837–53. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet. 1998;352:837–53.
27.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet. 1998;352:854–65. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet. 1998;352:854–65.
28.
go back to reference Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–74.CrossRefPubMedPubMedCentral Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–74.CrossRefPubMedPubMedCentral
29.
go back to reference Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65:385–411.CrossRefPubMed Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65:385–411.CrossRefPubMed
30.
go back to reference Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.CrossRefPubMed Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.CrossRefPubMed
31.
go back to reference Adler AI. Cardiovascular risk reduction in diabetes: underemphasised and overdue. Messages from major trials. Clin Med. 2001;1:472–7.CrossRef Adler AI. Cardiovascular risk reduction in diabetes: underemphasised and overdue. Messages from major trials. Clin Med. 2001;1:472–7.CrossRef
32.
go back to reference Muhlestein JB, Anderson JL, Horne BD, Lavasani F, Maycock CA, Bair TL, et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J. 2003;146:351–8.CrossRefPubMed Muhlestein JB, Anderson JL, Horne BD, Lavasani F, Maycock CA, Bair TL, et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J. 2003;146:351–8.CrossRefPubMed
33.
go back to reference Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004;109:1497–502.CrossRefPubMed Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004;109:1497–502.CrossRefPubMed
34.
go back to reference Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, et al. Create-Ecla trial group investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005;293:437–46.CrossRefPubMed Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, et al. Create-Ecla trial group investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005;293:437–46.CrossRefPubMed
35.
go back to reference Apstein CS, Opie LH. A challenge to the metabolic approach to myocardial ischaemia. Eur Heart J. 2005;26:956–9.CrossRefPubMed Apstein CS, Opie LH. A challenge to the metabolic approach to myocardial ischaemia. Eur Heart J. 2005;26:956–9.CrossRefPubMed
36.
go back to reference Selye H. A syndrome produced by diverse nocuous agents. Nature. 1936;138:32.CrossRef Selye H. A syndrome produced by diverse nocuous agents. Nature. 1936;138:32.CrossRef
37.
go back to reference Opie LH. Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction. Relation to myocardial ischemia and infarct size Am J Cardiol. 1975;36:938–53.PubMed Opie LH. Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction. Relation to myocardial ischemia and infarct size Am J Cardiol. 1975;36:938–53.PubMed
38.
go back to reference Landray MJ, Toescu V, Kendall MJ. The cardioprotective role of beta-blockers in patients with diabetes mellitus. J Clin Pharm Ther. 2002;27:233–42.CrossRefPubMed Landray MJ, Toescu V, Kendall MJ. The cardioprotective role of beta-blockers in patients with diabetes mellitus. J Clin Pharm Ther. 2002;27:233–42.CrossRefPubMed
39.
go back to reference Owen OE, Kalhan SC, Hanson RW. The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem. 2002;277:30409–12.CrossRefPubMed Owen OE, Kalhan SC, Hanson RW. The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem. 2002;277:30409–12.CrossRefPubMed
41.
go back to reference Bell DS. Advantages of a third-generation beta-blocker in patients with diabetes mellitus. Am J Cardiol. 2004;93:49B–52B.CrossRefPubMed Bell DS. Advantages of a third-generation beta-blocker in patients with diabetes mellitus. Am J Cardiol. 2004;93:49B–52B.CrossRefPubMed
43.
go back to reference Simon K, Surek R, Szamosi I, Dobó E, Nádasy T, Baltás E, et al. Role of non-ischaemic diabetic cardiomyopathy in induction of augmented cardiovascular risk. Cardiologia Hungarica. 2011;41:200–5 Simon K, Surek R, Szamosi I, Dobó E, Nádasy T, Baltás E, et al. Role of non-ischaemic diabetic cardiomyopathy in induction of augmented cardiovascular risk. Cardiologia Hungarica. 2011;41:200–5
44.
go back to reference Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective. Heart Fail Rev. 2002;7:187–203.CrossRefPubMed Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective. Heart Fail Rev. 2002;7:187–203.CrossRefPubMed
45.
go back to reference Stern MP. Diabetes and cardiovascular disease: the "common soil" hypothesis. diabetes. 1995;44:369–74.CrossRefPubMed Stern MP. Diabetes and cardiovascular disease: the "common soil" hypothesis. diabetes. 1995;44:369–74.CrossRefPubMed
46.
go back to reference DeFronzo RA. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia. 1992;35:389–97.CrossRefPubMed DeFronzo RA. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia. 1992;35:389–97.CrossRefPubMed
47.
go back to reference Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327:707–13.CrossRefPubMed Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327:707–13.CrossRefPubMed
48.
go back to reference Winkler G, Salamon F, Salamon D, Speer G, Simon K, Cseh K. Elevated serum tumour necrosis factor-alpha levels can contribute to the insulin resistance in type II (non-insulin-dependent) diabetes and in obesity. Diabetologia. 1998;41:860–1.CrossRefPubMed Winkler G, Salamon F, Salamon D, Speer G, Simon K, Cseh K. Elevated serum tumour necrosis factor-alpha levels can contribute to the insulin resistance in type II (non-insulin-dependent) diabetes and in obesity. Diabetologia. 1998;41:860–1.CrossRefPubMed
49.
go back to reference Taskinen MR. Lipid metabolism in diabetes. In: Taskinen R, editor. Diabetes int the new millenium. Philadelphia: W.B. Saunders Company; 2000. p. 32–55. Taskinen MR. Lipid metabolism in diabetes. In: Taskinen R, editor. Diabetes int the new millenium. Philadelphia: W.B. Saunders Company; 2000. p. 32–55.
50.
go back to reference Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.CrossRefPubMed Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.CrossRefPubMed
51.
go back to reference van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–67.CrossRef van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–67.CrossRef
Metadata
Title
Can blood glucose value really be referred to as a metabolic parameter?
Authors
Kornél Simon
István Wittmann
Publication date
01-06-2019
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 2/2019
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-019-09504-0

Other articles of this Issue 2/2019

Reviews in Endocrine and Metabolic Disorders 2/2019 Go to the issue